Funding for this study was primarily provided by the Mayo Clinic Center for Individualized Medicine. In addition, Drs. Vande Voort and Croarkin were co-primary investigators on this investigator-initiated study that had a grant-in-kind for supplies and genotyping only through Assurex Health, Inc. Assurex Health, Inc. did not have any role in the development or design of the study, collection of data, statistical analysis, interpretation of data, writing of the manuscript, or decision for publication of this study.

Consent has been provided for descriptions of specific patient information.

This study was presented at the American Academy of Child and Adolescent Psychiatry 66th Annual Meeting, October 14−19, 2019, Chicago, Illinois.

Ms. Geske served as the statistical expert for this research.

Author Contributions

Conceptualization: Vande Voort, Geske, Frye, Croarkin

Data curation: Vande Voort, Orth, Shekunov, Ward, Croarkin

Formal analysis: Vande Voort, Geske, Frye, Croarkin

Funding acquisition: Frye, Croarkin

Investigation: Vande Voort, Orth, Shekunov, Romanowicz, Ward, Frye, Croarkin

Methodology: Vande Voort, Geske, Frye, Croarkin

Project administration: Vande Voort, Orth, Shekunov, Ward, Frye, Croarkin

Resources: Frye, Croarkin

Supervision: Vande Voort, Orth, Shekunov, Romanowicz, Geske, Frye, Croarkin

Validation: Vande Voort, Croarkin

Writing – original draft: Vande Voort, Geske, Croarkin

Writing – review and editing: Vande Voort, Orth, Shekunov, Romanowicz, Geske, Ward, Leibman, Frye, Croarkin

ORCID

Jennifer L. Vande Voort, MD: https://orcid.org/0000-0002-3630-4773

Scott S. Orth, DO: https://orcid.org/0000-0001-7870-4591

Julia Shekunov, MD: https://orcid.org/0000-0002-9865-0735

Magdalena Romanowicz, MD: https://orcid.org/0000-0002-4916-0625

Jennifer R. Geske, MS: https://orcid.org/0000-0002-7341-1535

Jessica A. Ward, BA: https://orcid.org/0000-0001-5983-1720

Nicole I. Leibman, MD: https://orcid.org/0000-0002-4669-4576

Mark A. Frye, MD: https://orcid.org/0000-0001-6997-4215

Paul E. Croarkin, DO, MS: https://orcid.org/0000-0001-6843-6503

The authors gratefully thank the participants and their families who participated in this study.

Disclosure: All authors are currently employed or have been employed by the Mayo Clinic, which had a prior financial interest in Assurex Health, Inc. and currently has a financial interest in OneOme and the technology referenced with this publication. Dr. Vande Voort has served as a site primary investigator for a multicenter study funded by the National Networks of Depression Centers. Dr. Leibman has received grant funding through the National Institute of General Medical Sciences of the National Institutes of Health (NIH; T32 GM008685). Dr. Frye has received grant funding through the Mayo Foundation, Medibio, and Assurex Health, Inc. He has been a consultant for Actify Neurotherapies, Allergan, Intra-Cellular Therapies, Inc., Janssen, Myriad, Neuralstem Inc., Sanofi, Takeda, and Teva Pharmaceuticals. He has received CME/travel/honoraria through American Physician Institute, CME Outfitters, and Global Academy for Medical Education. Dr. Croarkin has received research support from NIH. He has received research grant support from Pfizer, Inc. and equipment support from Neuronetics, Inc. and MagVenture, Inc. He has been the primary investigator for a multicenter study funded by Neuronetics, Inc. and a site primary investigator for a study funded by NeoSync, Inc. He has served as a paid consultant for Procter and Gamble Company and Myriad Neuroscience. Drs. Orth, Shekunov, Romanowicz and Mss. Geske and Ward have reported no biomedical financial interests or potential conflicts of interest.